NPPB

Across TCGA pan-cancer cohorts, NPPB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NPPB data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher NPPB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPPB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, OV, and UCEC are the cancer types where NPPB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	42	view →
OV	OS	Median	II,III,IV	0.261	0.843	<.001	18	view →
UCEC	OS	Median	II,III,IV	1.000	0.461	.018	18	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NPPB–KIRC (DFS)

Open the KIRC breakdown →